Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 8:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 229 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
DE-104 medium concentration, DE-104 high concentration, Placebo, 0.005% latanoprost
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Artesia, California • Pasadena, California • San Francisco, California + 3 more
Completed No phase listed Observational Results available

Open Label Extension of LipoLat-CS202

NCT02599688
Conditions
Glaucoma
Interventions
Observation only
Other
Lead sponsor
Peregrine Ophthalmic
Industry
Eligibility
18 Years to 99 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Goose Creek, South Carolina
Conditions
Glaucoma
Interventions
Brinzolamide 1% and timolol 0.5% fixed combination eye drops
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
20 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Conditions
Glaucoma
Interventions
Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure, placebo eye drops
Drug · Procedure · Other
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Dothan, Alabama
Conditions
Open-Angle Glaucoma
Interventions
XEN45 (Glaucoma Gel Stent)
Device
Lead sponsor
AbbVie
Industry
Eligibility
45 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
23
States / cities
Fayetteville, Arkansas • Pasadena, California • Ventura, California + 19 more
Conditions
Glaucoma Open-Angle Primary, Glaucoma, Open Angle Glaucoma, Glaucoma, Open-Angle
Interventions
Mitomycin C
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
20 Years to 85 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
4
States / cities
Arcadia, California • Fountain Valley, California • Los Angeles, California + 1 more
Conditions
Visual Field Defect, Peripheral, Glaucoma, Open-Angle
Interventions
Vitamin B3, Pyruvate, Placebo
Dietary Supplement
Lead sponsor
Columbia University
Other
Eligibility
40 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Conditions
Open-angle Glaucoma or Ocular Hypertension
Interventions
DE-117 ophthalmic solution, latanoprost ophthalmic solution, Placebo
Drug · Other
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
7
States / cities
Newport Beach, California • Morrow, Georgia • Kansas City, Missouri + 4 more
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Travoprost Ophthalmic Topical Cream low-dose, Travoprost Ophthalmic Topical Cream mid-dose, Travoprost Ophthalmic Topical Cream high-dose, Timolol maleate ophthalmic solution, 0.5%, Travoprost Ophthalmic Solution, 0.004%
Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Newport Beach, California
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
PG324 Ophthalmic Solution 0.01%, PG324 Ophthalmic Solution 0.02%, Netarsudil (AR-13324) Ophthalmic Solution 0.02%, Latanoprost Ophthalmic Solution 0.005%
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
23
States / cities
Artesia, California • Inglewood, California • Newport Beach, California + 20 more
Conditions
Primary Open-angle Glaucoma (POAG), Ocular Hypertension
Interventions
SHP639 (n=60), Placebo Comparator (n=24)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 90 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lexington, Massachusetts
Conditions
Glaucoma, Glaucoma, Open-Angle, Glaucoma; Drugs, Droopy Eyelid, Ptosis, Glaucoma, Primary Open Angle
Interventions
brimonidine tartrate ophthalmic solution 0.025%, sterile balanced saline solution
Drug · Other
Lead sponsor
Tulane University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
1
States / cities
New Orleans, Louisiana
Conditions
Glaucoma, Ocular Hypertension
Interventions
OTX-TP, Timolol
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Fayetteville, Arkansas
Conditions
Open Angle Glaucoma, Primary Open Angle Glaucoma, Pseudoexfoliation Glaucoma, Pigmentary Glaucoma
Interventions
Hydrus Microstent, Ophthalmic surgery
Device · Procedure
Lead sponsor
Alcon Research
Industry
Eligibility
45 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Bentonville, Arkansas • Zephyrhills, Florida • Fraser, Michigan + 2 more
Completed Phase 1Phase 2 Interventional Results available

H-1337 Ophthalmic Solution Phase 1/2

NCT03452033
Conditions
Glaucoma, Open-Angle
Interventions
H-1337 Placebo, H-1337 [1], H-1337 [2], H-1337 [3]
Drug
Lead sponsor
Allysta Pharmaceutical
Industry
Eligibility
18 Years to 99 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Goose Creek, South Carolina
Conditions
Open Angle Glaucoma, Ocular Hypertension, Pseudoexfoliation Syndrome
Interventions
Travatan, Azopt, Alphagan P
Drug
Lead sponsor
Hermann Eye Center
Other
Eligibility
35 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
21
States / cities
Los Angeles, California • Hamden, Connecticut • Gainesville, Florida + 14 more
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
PF-04217329, latanoprost vehicle, latanoprost
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
8
States / cities
Cypress, California • Garden Grove, California • Gardena, California + 4 more
Completed Phase 1 Interventional Accepts healthy volunteers

Open-Label Study of Safety of H1337 in Healthy Volunteers

NCT06572397
Conditions
Glaucoma Open-Angle Primary, Ocular Hypertension
Interventions
H-1337 1.0%
Drug
Lead sponsor
D. Western Therapeutics Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Newport Beach, California
Conditions
Glaucoma
Interventions
Triesence, balanced salt solution BSS
Drug
Lead sponsor
Wills Eye
Other
Eligibility
21 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Glaucoma, Ocular Hypertension
Interventions
RKI983
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Timeline
Started 2007
U.S. locations
5
States / cities
Artesia, California • Rochester, New York • Charlotte, North Carolina + 2 more
Conditions
Open Angle Glaucoma
Interventions
Streamline Surgical System, iStent Inject W
Device
Lead sponsor
New World Medical, Inc.
Industry
Eligibility
22 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
18
States / cities
Fayetteville, Arkansas • Newport Beach, California • Torrance, California + 15 more
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
T-2345, Xalatan
Drug
Lead sponsor
Nephron Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
El Paso, Texas
Conditions
Glaucoma, Open-Angle [C11.525.381.407]
Interventions
Open angle glaucoma - iDropper device
Device
Lead sponsor
Care Team Solutions
Industry
Eligibility
21 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Glaucoma, Open-angle, Ocular Hypertension (OHT), Phacoemulsification Cataract Surgery
Interventions
iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery, Sham procedure in conjunction with cataract surgery
Combination Product · Procedure
Lead sponsor
Glaukos Corporation
Industry
Eligibility
45 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Kenosha, Wisconsin